Withhold hCG in cases where the ovarian monitoring suggests an increased risk of ovarian hyperstimulation syndrome (OHSS) on the last day of GONAL-f therapy (for example estradiol greater than 2,000 pg per mL) [see Warnings and Precautions (5.2, 5.3, 5.5, 5.11)]
Phase 1 initiation H2 2026
Targeting Specific Areas Possible : Instead of flowing throughout the entire body, it is concentrated and absorbed into the facial skin where pigment and tone improvement are needed
Malavazos AE, Iacobellis G, Dozio E, Basilico S, Di Vincenzo A, Dubini C, et al
This is one reason genetic testinglike PlexusDx's Precision Peptide Genetic Testhelps inform your optimal timing and dosing approach, since individual variations in GLP-1 receptor sensitivity affect how quickly your body responds